2022 AAPM 64th Annual Meeting
Back to session list

Session Title: IROC - Who is Who in Support of NCI Clinical Trials
Question 1: 1. Which of the following is NOT a core service of IROC:
Reference:FitzGerald TJ. A new model for imaging and radiation therapy quality assurance in the National Clinical Trials Network of the National Cancer Institute. Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):272-3.
Choice A:Site qualification
Choice B:Credentialing
Choice C:Protocol Development
Choice D:Car Washing
Choice E:Case Review
Choice F:Data Management
Question 2: 2. The purpose of IROC’s end-to-end RT credentialing phantoms are to:
Reference:Molineu A, Followill DS, Balter PA, Hanson WF, Gillin MT, Huq MS, Eisbruch A, Ibbott GS. Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):577-83.
Choice A:Verify that plan quality matches the protocol requirements
Choice B:Verify that contouring processes are consistent with protocol requirements
Choice C:Verify that the intended and delivered dose agree
Choice D:Verify that protocol-specific dose constraints are used
Question 3: The standardization of structure names is a critical component of making shared data more accessible and usable to benefit patient care.
Reference:AAPM Task Group Report 263
Choice A:True
Choice B:False
Question 4: Individualized dosimetry treatment planning is not necessary for radiopharmaceutical therapy.
Reference:Garin et al. Lancet Gastroenterol Hepatol 2021
Choice A:True
Choice B:False
Question 5: What is TRIAD used for?
Reference:Bibb Allen, David C. Levin, Michael Brant-Zawadzki, Frank James Lexa, Richard Duszak, ACR White Paper: Strategies for Radiologists in the Era of Health Care Reform and Accountable Care Organizations: A Report From the ACR Future Trends Committee, Journal of the American College of Radiology, Volume 8, Issue 5, 2011, Pages 309-317
Choice A:Spearfishing
Choice B:Study image submission and site accreditation
Choice C:Site qualification and study image submission
Choice D:Site qualification and site accreditation
Question 6: What of the following are not among the benefits of blinded, independent central review (BICR) in cancer trials?
Reference:Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., & Mooney, M. M. (2008). Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(22), 3791–3796.
Choice A:Gives radiologists valuable exposure to cancer images
Choice B:Help achieve unbiased results by minimizing differences in subjective imaging endpoint evaluation across sites and readers in a multicenter study
Choice C:Better discern the reliability of marginal results, particularly from local reads
Choice D:Minimize bias in evaluation of progression introduced by knowledge of treatment arm assignment
Back to session list